LAPTM4B Allele *2 is Associated with Breast Cancer Susceptibility and Prognosis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Sep 18

PMID 22984585

Citations 14

Authors

Xiaoyan Li

Xiangnan Kong

Xi Chen

Ning Zhang

Liyu Jiang

Tingting Ma

Qifeng Yang

Affiliations

Soon will be listed here.

Abstract

Background: Lysosome-associated protein transmembrane 4 beta (LAPTM4B) has two alleles named LAPTM4B*1 and LAPTM4B*2. Allele *1 contains only one copy of a 19-bp sequence at the 5'UTR in the first exon, whereas this sequence of allele*2 is duplicated and arrayed as a tandem repeat. Previous studies revealed that LAPTM4B polymorphisms contribute to the risk of certain types of cancers. This study aimed to investigate the polymorphism of LAPTM4B in breast cancer by analysis the correlation of LAPTM4B genotype with breast cancer susceptibility, clinicopathologic features and prognosis.

Methods: Genotyping of the LAPTM4B polymorphism was determined by PCR method. The expression levels of LAPTM4B in breast cancer tissues and breast cancer cell lines were determined by quantitative reverse-transcription PCR (qRT-PCR) analysis. The correlation of LAPTM4B genotype with clinicopathologic parameters and prognosis were assessed statistically.

Results: The results of qRT-PCR analysis indicated that LAPTM4B*2 was associated with the higher level of LAPTM4B expression compared with the LAPTM4B*1 in both breast cancer cell lines and breast cancer tissues. We found that LAPTM4B*2 was associated with an increased risk for breast cancer. LAPTM4B*2 was significantly associated with higher histopathologic grade, lymph node metastasis and poor prognosis.

Conclusion: LAPTM4B*2 is a risk factor associated with breast cancer susceptibility and poor prognosis. LAPTM4B*2 may be a potential predicative marker for the susceptibility, progression and metastasis of breast cancer.

Citing Articles

LAPTM4B gene polymorphism augments the risk of cancer: Evidence from an updated meta-analysis.

Hashemi M, Bahari G, Tabasi F, Markowski J, Malecki A, Ghavami S J Cell Mol Med. 2018; 22(12):6396-6400.

PMID: 30255662 PMC: 6237586. DOI: 10.1111/jcmm.13896.

Association between gene polymorphism and susceptibility to and prognosis of diffuse large B-cell lymphoma.

Ding H, Cheng X, Ding N, Tian Z, Zhu J, Zhou C Oncol Lett. 2018; 15(1):264-270.

PMID: 29387221 PMC: 5768069. DOI: 10.3892/ol.2017.7318.

Increased levels of LAPTM4B, VEGF and survivin are correlated with tumor progression and poor prognosis in breast cancer patients.

Li S, Wang L, Meng Y, Chang Y, Xu J, Zhang Q Oncotarget. 2017; 8(25):41282-41293.

PMID: 28476037 PMC: 5522199. DOI: 10.18632/oncotarget.17176.

Association between gene polymorphism and prostate cancer susceptibility in an Iranian population.

Hashemi M, Rezaei M, Narouie B, Simforoosh N, Basiri A, Ziaee S Mol Cell Oncol. 2017; 3(6):e1169342.

PMID: 28090574 PMC: 5160414. DOI: 10.1080/23723556.2016.1169342.

Relationship between LAPTM4B Gene Polymorphism and Prognosis of Patients following Tumor Resection for Colorectal and Esophageal Cancers.

Cheng X, Tian X, Wu X, Xing X, Du H, Zhou C PLoS One. 2016; 11(7):e0158715.

PMID: 27391361 PMC: 4938575. DOI: 10.1371/journal.pone.0158715.

References

Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y . Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med. 2010; 16(2):214-8. PMC: 2826790. DOI: 10.1038/nm.2090. View

Meng F, Song H, Luo C, Yin M, Xu Y, Liu H . Correlation of LAPTM4B polymorphisms with cervical carcinoma. Cancer. 2011; 117(12):2652-8. DOI: 10.1002/cncr.25833. View

Yu J, Ding S, Chang C, Kuo S, Chen S, Hsu G . Genetic susceptibility to the development and progression of breast cancer associated with polymorphism of cell cycle and ubiquitin ligase genes. Carcinogenesis. 2009; 30(9):1562-70. DOI: 10.1093/carcin/bgp173. View

Li L, Wei X, Pan Y, Li H, Yang H, He Q . LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene. 2010; 29(43):5785-95. DOI: 10.1038/onc.2010.303. View

Rodriguez S, Gaunt T, Day I . Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol. 2009; 169(4):505-14. PMC: 2640163. DOI: 10.1093/aje/kwn359. View

Xu Y, Liu Y, Zhou R, Meng F, Gao Y, Yang S . LAPTM4B polymorphisms is associated with ovarian cancer susceptibility and its prognosis. Jpn J Clin Oncol. 2012; 42(5):413-9. DOI: 10.1093/jjco/hys026. View

Yin M, Xu Y, Lou G, Hou Y, Meng F, Zhang H . LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis. Int J Cancer. 2010; 129(3):629-35. DOI: 10.1002/ijc.25689. View

Yang H, Zhai G, Ji X, Xiong F, Su J, McNutt M . Correlation of LAPTM4B polymorphisms with gallbladder carcinoma susceptibility in Chinese patients. Med Oncol. 2012; 29(4):2809-13. DOI: 10.1007/s12032-012-0173-4. View

Zhou L, He X, Chen J, Cui Q, Qu Q, Rui J . Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma. Eur J Cancer. 2007; 43(4):809-15. DOI: 10.1016/j.ejca.2006.10.025. View

10.

Shao G, Zhou R, Zhang Q, Zhang Y, Liu J, Rui J . Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene. 2003; 22(32):5060-9. DOI: 10.1038/sj.onc.1206832. View

11.

Zhou L, He X, Cui Q, Zhou W, Qu Q, Zhou R . Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. Cancer Lett. 2008; 264(2):209-17. DOI: 10.1016/j.canlet.2008.01.025. View

12.

Ronnov-Jessen L, Petersen O, Bissell M . Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev. 1996; 76(1):69-125. DOI: 10.1152/physrev.1996.76.1.69. View

13.

Yin M, Lou C, Zhang W, Meng F, Zhang H, Ning X . LAPTM4B overexpression is a novel independent prognostic marker for metastatic ovarian tumors. Int J Gynecol Cancer. 2011; 22(1):54-62. DOI: 10.1097/IGC.0b013e318234f9ac. View

14.

Liu X, Zhou R, Zhang Q, Zhang Y, Shao G, Jin Y . [Identification and characterization of LAPTM4B encoded by a human hepatocellular carcinoma-associated novel gene]. Beijing Da Xue Xue Bao Yi Xue Ban. 2003; 35(4):340-7. View

15.

Mavaddat N, Antoniou A, Easton D, Garcia-Closas M . Genetic susceptibility to breast cancer. Mol Oncol. 2010; 4(3):174-91. PMC: 5527934. DOI: 10.1016/j.molonc.2010.04.011. View

16.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

17.

Liu Y, Zhang Q, Qian N, Zhou R . Relationship between LAPTM4B gene polymorphism and susceptibility of gastric cancer. Ann Oncol. 2006; 18(2):311-6. DOI: 10.1093/annonc/mdl394. View

18.

Zhang N, Li X, Tao K, Jiang L, Ma T, Yan S . BCL-2 (-938C > A) polymorphism is associated with breast cancer susceptibility. BMC Med Genet. 2011; 12:48. PMC: 3078853. DOI: 10.1186/1471-2350-12-48. View

19.

Zhai G, Yang H, Ji X, Xiong F, Su J, McNutt M . Correlation of LAPTM4B polymorphisms with hepatocellular carcinoma in Chinese patients. Med Oncol. 2011; 29(4):2744-9. DOI: 10.1007/s12032-011-0139-y. View

20.

Liu X, Xiong F, Wei X, Yang H, Zhou R . LAPTM4B-35, a novel tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of hepatocellular carcinoma cells. Cancer Sci. 2009; 100(12):2335-40. PMC: 11158284. DOI: 10.1111/j.1349-7006.2009.01346.x. View